Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review.
Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review. Cancers (Basel). 2025 Apr 16; 17(8).
PMID: 40282513
Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone.
Prebiopsy Magnetic Resonance Imaging Followed by Combination Biopsy for Prostate Cancer Diagnosis Is Associated with a Lower Risk of Biochemical Failure After Treatment Compared to Systematic Biopsy Alone. Diagnostics (Basel). 2025 Mar 12; 15(6).
PMID: 40150041
Outcomes of Salvage Radical Prostatectomy after Focal Therapy.
Outcomes of Salvage Radical Prostatectomy after Focal Therapy. World J Urol. 2025 Feb 06; 43(1):106.
PMID: 39912914
Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025;87:526-533.
Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025;87:526-533. Eur Urol. 2025 May; 87(5):e89-e90.
PMID: 39863507
Shifting tides: A survey analysis of urologists' evolving attitudes toward focal therapy for prostate cancer.
Shifting tides: A survey analysis of urologists' evolving attitudes toward focal therapy for prostate cancer. Indian J Urol. 2025 Jan-Mar; 41(1):59-65.
PMID: 39886635
Prostate ablation for the management of localized prostate cancer.
Prostate ablation for the management of localized prostate cancer. Urol Oncol. 2025 Mar; 43(3):194.e9-194.e17.
PMID: 39592359
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879.
PMID: 39529961
Editorial Comment.
Editorial Comment. J Urol. 2024 Dec; 212(6):872.
PMID: 39263971
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial.
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial. Cancers (Basel). 2024 Jun 08; 16(12).
PMID: 38927884
A narrative clinical trials review in the realm of focal therapy for localized prostate cancer.
A narrative clinical trials review in the realm of focal therapy for localized prostate cancer. Transl Cancer Res. 2024 Nov 30; 13(11):6529-6539.
PMID: 39697719